USO 14206: A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination with Ibrutinib Compared to Ibrutinib Alone, in Patients with Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL). Save

Date Added
March 29th, 2015
PRO Number
Pro00043579
Researcher
Suzanne Fanning

List of Studies

Keywords
Blood Disorders, Cancer/Leukemia
Summary

This study is for patients who have been previously treated for Chronic Lymphocytic Leukemia (or CLL), and have at least one high-risk cytogenetic abnormality (17p deletion, 11q deletion and/or P53 gene mutation).
The study is being done to determine how effective the combination of an investigational drug (ublituximab) and another currently FDA approved drug ibrutinib (also referred to as Imbruvica®) is when given to patients without causing serious side effects.

Institution
Greenville
Recruitment Contact
Gina Norris
864-242-2762
gnorris@ghs.org

Change_preferences

-- OR --

Create_login